Skip to main content

Sanofi says on track to regain solid position in cancer drugs

Submitted by CP Staff on
snippet

Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.

Source
Reuters

5 takeaways from the first look at cancer's biggest conference

Submitted by admin on
snippet

Every year tens of thousands of cancer researchers, doctors, investors and analysts travel to Chicago in early June for the annual meeting of the American Society of Clinical Oncology. It's the largest conference in the drug industry's hottest field. 

Source
Biopharma Dive

Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

Submitted by admin on
snippet

A Regeneron/Sanofi team has a target date for launching the world’s 6th PD-1/L1 checkpoint inhibitor. And while they may be late to the growing league of rivals — dominated by Bristol-Myers Squibb and Merck — they plan to enter with a market splash, with considerable assistance from FDA regulators who are steel keen to expand the field.

Source
Endpoints